Metastasis-associated protein 1 as a new prognostic marker for solid tumors: a meta-analysis of cohort studies

Metastasis-associated protein 1 (MTA1) is a molecular marker in various solid tumors that has recently been investigated. The prognostic significance of MAT1 expression remains controversial. In this work, we aimed to determine the relationship between immunohistochemistry-detected MAT1 expression and survival of patients with solid tumors by conducting a meta-analysis of cohort studies. Relevant studies were identified via an electronic database search updated on October 28, 2013. We included cohort studies that reported hazard ratios (HRs) or odds ratios (ORs) with 95 % confidence intervals (CIs) to determine the association of high MTA1 expression with overall survival (OS) and clinicopathological characteristics. Heterogeneity was quantified using I ² statistics, and publication bias was evaluated using funnel plots. Sensitivity analysis was conducted to evaluate the robustness of meta-analysis findings. We identified 16 cohort studies that focused on MTA1 overexpression and prognosis involving 2,253 cancer patients. Overall, the combined HR for OS was 1.85 (95 % CI: 1.55–2.28, P < 0.001). Omission of any single study had no significant effect on the pooled HR estimate. When the studies were stratified by tumor type, similar results of poor prognosis were observed in non-small cell lung cancer (HR = 2.05, 95 % CI: 1.14–3.68, P = 0.016) and esophageal squamous cell carcinoma (HR = 1.86, 95 % CI: 1.44–2.39, P < 0.001). Moreover, multivariate survival analysis showed that MTA1 overexpression was an independent predictor of poor prognosis (HR = 1.90, 95 % CI: 1.53–2.37, P < 0.001). In addtional, MTA1 overexpression was significantly associated with tumor size (OR = 2.72, 95 % CI = 1.44–5.14, P = 0.002), tumor stage (OR = 2.44, 95 % CI = 1.67–3.57, P < 0.001), depth of invasion (OR = 2.63, 95 % CI = 1.74–3.97, P < 0.001), and lymph node metastasis (OR = 2.57, 95 % CI = 1.57–4.19, P < 0.001). However, when age, sex, and tumor differentiation were considered, no obvious association was observed. This study provides a comprehensive examination of the literature available on the association of MTA1 overexpression with OS and some clinicopathological features in solid tumors. Meta-analysis results provide evidence that MTA1 may be a new indicator of poor cancer prognosis. Considering the limitations of the eligible studies, other large-scale prospective trials must be conducted to clarify the prognostic value of MTA1 in predicting cancer survival.